Last reviewed · How we verify

Baraclude — Competitive Intelligence Brief

Baraclude (ENTECAVIR) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: entecavir. Area: Infectious Disease.

marketed entecavir Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Baraclude (ENTECAVIR) — Bristol-Myers Squibb. Entecavir works by inhibiting the replication of the hepatitis B virus.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Baraclude TARGET ENTECAVIR Bristol-Myers Squibb marketed entecavir 2005-01-01
Entecavir + Fuzheng Huayu Tablet Entecavir + Fuzheng Huayu Tablet ShuGuang Hospital marketed Nucleoside reverse transcriptase inhibitor (entecavir component); traditional Chinese medicine formulation (Fuzheng Huayu component) HBV polymerase/reverse transcriptase (entecavir); multiple targets including hepatic stellate cells and inflammatory pathways (Fuzheng Huayu)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (entecavir class)

  1. Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Baraclude — Competitive Intelligence Brief. https://druglandscape.com/ci/entecavir. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: